Data on mRNA vaccines sent by Moderna to European regulators before the COVID-19 outbreak included early tests of the mRNA ...

There are currently three vaccine candidates moving through the clinical pipeline in human trials right now, and the furthest along is Moderna, which has developed a norovirus vaccine with the ...

Moderna conducts phase 3 trial for norovirus vaccine as cases rise in the U.S., with results expected in late 2025 or early 2026.

Moderna (NASDAQ: MRNA) was one of the hottest companies of early pandemic times, delivering a coronavirus vaccine to market in record time and quickly generating blockbuster revenue from it.

Massachusetts-based Moderna will likely be the first to manufacture a bird flu vaccine, backed by hundreds of millions in government funding. The biopharmaceutical giant is developing the vaccine ...

Challenges such as declining vaccination rates and regulatory uncertainties for manufacturing plants in key markets like the UK, Canada, and Australia also impacts the company, with Moderna also ...

Moderna's revenue and stock price have steadily declined since global demand for COVID-19 vaccines has dwindled. During 2020 and 2021, the company generated massive revenues, fueled by its ...

In 2023, Moderna initiated a study on a “pandemic influenza vaccine” to protect against H5 and H7 avian influenza viruses. In July, the company received $176 million from HHS toward its ...

Shares of Moderna plunged 20% Monday after the vaccine maker slashed its forecast of full-year 2025 revenue, as sales of its vaccines against Covid-19 and respiratory syncytial virus continue to ...

Moderna has been awarded approximately $590 million from the federal government to help speed up the development of an mRNA-based bird flu vaccine, health officials said.

Moderna's mRNA technology gained rapid validation as sales of its covid vaccine soared in 2021 and 2022, but we think the firm has yet to secure a narrow economic moat around its business ...

Moderna Inc. shares plunged after the company slashed its sales forecast for this year as it struggles with slow demand for its Covid and RSV vaccines. The Cambridge, Massachusetts-based company ...